Respiratory syncytial virus (RSV) is a respiratory virus that can cause infection in the upper (nose and throat) and lower (airways and lungs) parts of a person’s respiratory system. It is a common cause of respiratory illness, particularly among infants, young children and older adults during the fall respiratory season. Immunization is available to help prevent serious outcomes, such as hospitalization, caused by the virus.
RSV immunization
For the 2024/2025 season, the following RSV products are available:
- Beyfortus® immunoglobulin: For infants and high-risk children to prevent serious RSV infections.
- Abrysvo® vaccine: For pregnant individuals to provide protection to infants from birth to six months of age.
- Arexvy vaccine: Adults ages 60 and older to prevent lower respiratory tract disease (LRTD) caused by RSV.
Eligibility
Publicly funded (free)
- Infants: Eligible if born in 2024 or during the RSV season, or if they have specific health conditions (e.g., chronic lung disease, congenital heart disease).
- Pregnant Individuals: Available for those between 32 and 36 weeks of pregnancy.
- Older Adults: Individuals aged 60 and older who are residents of long-term care homes or have specific health conditions, and did not receive the vaccine last year.
Not Publicly funded (At a cost)
The RSV vaccine is available for adults 60 and older (who did not receive the vaccine last year) at a cost of approximately $250. You can also check if it is covered under your drug or benefit plan.
How to book an appointment for RSV immunization
Those eligible for an RSV product can book an appointment in the following ways:
- Contact your doctor or primary care provider.
- If you are unable to book with your doctor or primary care provider or do not have one, contact Public Health at 1-800-265-7293 ext. 7006. Leave a message if prompted.
Resources